Explore the words cloud of the RAPID project. It provides you a very rough idea of what is the project "RAPID" about.
The following table provides information about the project.
|Coordinator Country||Sweden [SE]|
|Total cost||2˙902˙248 €|
|EC max contribution||2˙031˙574 € (70%)|
1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
|Duration (year-month-day)||from 2018-11-01 to 2020-10-31|
Take a look of project's partnership.
Klaria's business concept is based on developing and commercializing innovative, fast-acting medicinal products with clear competitive benefits in the therapeutic fields of migraine and cancer-related pain. Migraine is the sixth most disabling illness in the world. The economic burden of migraine predominantly falls on patients and their employers in the form of bedridden days and lost productivity. The illness is three times as common in women than in men. However, existing drug delivery methods are not effective which results in low therapy satisfaction rates amongst migraine patients.
Klaria developed an alginate-based polymer film capable of rapidly delivering the API (active pharmaceutical ingredient) directly into the bloodstream. The thin film is similar to a small postage stamp and is discreetly attached to the oral mucous membrane and allows the medication to be distributed into the bloodstream through the oral mucous membrane. The substance is delivered much more quickly (and thereby has a faster impact) than substances which are swallowed in tablets or capsules. Klaria’s film does not require taking an injection or suppository and ensures early intervention which is critical in order for migraine patients to experience pain relief. The film can be used by all migraine patients using medications based on triptans including those who experience concomitant vomiting during their migraine attack.
Project RAPID, aims therefore to exploit the positive clinical performance of the buccal adhesive film, the company’s IP position and its ability to manufacture cost-effectively to launch an innovative migraine to contribute to an improved quality of life for migraine patients.
|Dissemination material||Documents, reports||2020-02-12 16:52:58|
Take a look to the deliverables list in detail: detailed list of RAPID deliverables.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RAPID" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (email@example.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "RAPID" are provided by the European Opendata Portal: CORDIS opendata.
Standardised administration device for raw medical herbsRead More
MCBD (MULTI-CORE BIOPSY DEVICE) INNOVATIVE BIOPSY TECHNOLOGY FOR THE NEW ERA OF TARGETED MEDICINERead More
CAARESYS: vehicle passenger monitoring system based on contactless low emission radio frequency radar.Read More